Drug-Loaded Biodegradable Microbeads for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current embolic agents for chemoembolization therapy lack preloaded drug capability and have suboptimal pharmacokinetic release profiles, leading to inefficient drug delivery and limited duration of action, particularly in treating hepatocellular carcinoma.
Innovation Solution
Development of drug-loaded microbead compositions comprising water-swellable polymer materials with therapeutic agents chemically bonded to carriers, allowing for sustained release of multiple therapeutic agents like sorafenib and doxorubicin over extended periods, embedded within biodegradable materials such as liposomes or ethosomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If embolic agents are provided without preloaded drug, then the embolic agents can be prepared and stored easily, but the physician must order pharmacy to load drug into embolic agent well in advance of surgery (at least 24 hours before), resulting in loss of time and reduced productivity
Solution Approach 1:
The patent applies preliminary action by pre-loading the embolic microbeads with therapeutic agents during the manufacturing process. The drug-loaded microbeads are prepared in advance, sterilized, and stored ready for use. This eliminates the need for pharmacy personnel to load drugs into embolic agents 24 hours before surgery, as the microbeads arrive at the procedure already loaded with the therapeutic agent.
Solution Approach 2:
The patent merges the embolic agent and therapeutic agent into a single integrated product. The microbeads are manufactured with the therapeutic agent already incorporated into or onto the microbead structure, combining the embolization function and drug delivery function into one unified product that requires no separate drug loading step.
2Device complexity
If embolic agents use suboptimal pharmacokinetic release profile, then the agent structure can be simpler, but the drug release stops after only a few days (typically within 3 days), resulting in reduced duration of action
Solution Approach 1:
The patent employs composite materials by combining biodegradable polymer matrices with therapeutic agents. The microbeads are made from biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), or polyglycolic acid (PGA), which provide controlled drug release through biodegradation. This composite structure enables sustained release over weeks to months while maintaining relatively simple microbead fabrication processes.
Solution Approach 2:
The patent utilizes porous microbead structures that allow controlled diffusion of therapeutic agents. The biodegradable polymer matrix is formulated to create a porous network that enables gradual drug release through diffusion and erosion mechanisms, extending the duration of action from days to weeks or months without requiring complex multi-layer structures.
3Reliability
If embolic agents are used for hepatocellular carcinoma treatment, then the treatment can address this high-mortality disease, but the current agents lack sustained delivery capability, resulting in insufficient treatment efficacy
Solution Approach 1:
The patent implements continuity of useful action through sustained drug release from the microbeads. The biodegradable polymer matrix continuously releases the therapeutic agent over an extended period (weeks to months) after implantation in the hepatic artery. This continuous delivery ensures prolonged exposure of the hepatocellular carcinoma tumor to the therapeutic agent, improving treatment efficacy compared to conventional agents that release drug within 3 days.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microbead compositions provide a continuous and sustained release of therapeutic agents for at least 7 days, reducing the need for preloading and improving treatment efficacy for conditions like hepatocellular carcinoma by ensuring prolonged drug delivery directly to the treatment site.
Implementation Method 1
microbeads comprising a water-swellable polymer material
Implementation Method 2
biodegradable drug-eluting particles
Implementation Method 3
biodegradable polymer materials
Implementation Method 4
a complex comprising a carrier and a therapeutic agent chemically bonded to the carrier
Data Source
AI summary
Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.